Specialized Bilayer Tablets for Extreme Environments and High-Risk Applications

Publication ID: 24-11857684_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Bilayer Tablets for Extreme Environments and High-Risk Applications,” Published Technical Disclosure No. 24-11857684_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857684_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,684.

Summary of the Inventive Concept

The present inventive concept discloses novel bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, specifically designed for high-altitude environments, disaster relief, extreme weather conditions, and high-security needs. These tablets provide rapid relief from cold and flu symptoms in challenging operational environments.

Background and Problem Solved

The original patent disclosed bilayer tablets comprising acetylsalicylic acid and pseudoephedrine. However, these tablets may not be suitable for use in extreme environments, such as high-altitude areas, disaster zones, or areas with limited access to medical care. The present inventive concept addresses these limitations by adapting the bilayer tablets for specific, narrow markets or unique operational environments.

Detailed Description of the Inventive Concept

The inventive concept comprises bilayer tablets with acetylsalicylic acid and pseudoephedrine, formulated to mitigate degradation at low atmospheric pressure, packaged in waterproof containers, coated with water-resistant layers, or integrated with water purification systems. The tablets may also be packaged in high-security containers with tamper-evident seals and GPS tracking devices. These specialized tablets provide rapid relief from cold and flu symptoms in challenging operational environments, ensuring optimal performance and efficacy.

Novelty and Inventive Step

The present inventive concept introduces novel and non-obvious adaptations of the original bilayer tablets for specific, narrow markets or unique operational environments. The inventive step lies in the combination of the original bilayer tablet composition with specialized formulations, packaging, and integration with other systems to address the unique challenges of high-altitude environments, disaster relief, extreme weather conditions, and high-security needs.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include bilayer tablets with modified release profiles, additional active pharmaceutical ingredients, or different excipients tailored for specific environments or applications. Variations may also include different packaging materials, shapes, or sizes to accommodate specific operational requirements.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of disaster relief, high-security operations, and extreme environment exploration. Target industries may include government agencies, humanitarian organizations, and private companies operating in challenging environments.

CPC Classifications

SectionClassGroup
A A61 A61K9/209
A A61 A61J3/10
A A61 A61K31/137
A A61 A61K31/616
A A61 A61K9/2009
A A61 A61K9/2018
A A61 A61K9/2054
A A61 A61K9/2059

Field of Art

Pharmaceutical formulation and drug delivery systems, specifically focused on bilayer tablet design for oral pharmaceutical compositions with multiple active ingredients

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical formulation scientist with expertise in tablet design, excipient selection, drug stability, and packaging technologies, holding at least a Master's degree in pharmaceutical sciences with 3-5 years of industrial experience in oral solid dosage form development

Obviousness Rationale

A PHOSITA would recognize that the specialized bilayer tablet variations represent predictable extensions of the source patent's core bilayer tablet technology, applying standard pharmaceutical engineering techniques to address specific environmental and operational challenges. The modifications involve routine packaging, coating, and formulation adaptations that are well within the ordinary skill set of pharmaceutical product developers. The PTD's variations demonstrate standard problem-solving approaches for extending pharmaceutical product utility to niche market segments.

Obvious Combinations & Variations

Source Patent Element
Bilayer tablet with acetylsalicylic acid and sodium carbonate granulation technique
PTD Variation
Bilayer tablet formulated to mitigate degradation at low atmospheric pressure
Obviousness Reasoning
A PHOSITA would recognize that drug stability modifications are a predictable design choice when adapting pharmaceutical formulations for extreme environments, using known excipient and coating technologies
Source Patent Element
Pharmaceutical tablet with defined layer composition
PTD Variation
Waterproof container packaging and water-resistant tablet coating
Obviousness Reasoning
Protective packaging and moisture-resistant coatings are standard pharmaceutical engineering solutions for improving product stability, representing a known technique for extending product utility
Source Patent Element
Bilayer tablet with multiple active pharmaceutical ingredients
PTD Variation
Integration with water purification systems and high-security packaging
Obviousness Reasoning
Combining pharmaceutical products with ancillary systems is a predictable design approach for creating multi-functional medical kits, utilizing standard packaging and integration technologies
Source Patent Element
Tablet formulation with defined granulation and excipient ratios
PTD Variation
Modified release profiles and tailored excipient combinations for specific environments
Obviousness Reasoning
Adjusting pharmaceutical formulation parameters for specific use cases represents a routine exercise of ordinary skill in pharmaceutical product development
Source Patent Element
Bilayer tablet with acetylsalicylic acid and pseudoephedrine
PTD Variation
High-security packaging with tamper-evident seals and GPS tracking
Obviousness Reasoning
Implementing track-and-trace technologies in pharmaceutical packaging is a predictable solution for improving product security and supply chain management
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857684 and the published technical disclosure, a person of ordinary skill in the art would find the claimed variations obvious, as they represent predictable extensions of known pharmaceutical formulation and packaging technologies. The disclosed modifications constitute routine engineering adaptations that would be apparent to a skilled artisan seeking to optimize bilayer tablet performance for specialized environmental and operational contexts.

Original Patent Information

Patent NumberUS 11,857,684
TitleOral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof
Assignee(s)BAYER AKTIENGESELLSCHAFT